Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Comorbidity Scales in Patients with Myeloproliferative Neoplasms: Which One Fits Best?

Susanne Isfort, MD, Andrea Kaifie, MD, Karla Bennemann, MD, Edgar Jost, MD, Jens Panse, MD, Tim H Bruemmendorf, MD, Steffen Koschmieder, MD

Blood (2014) 124 (21): 1828.

https://doi.org/10.1182/blood.V124.21.1828.1828

Published: 2014

Journal Articles

Diagnosis and Treatment of Myeloproliferative Neoplasms in Germany: First Results from the SAL-MPN Registry

Andrea Kaifie, MD, Susanne Isfort, MD, Dominik Wolf, MD, Mathias Hanel, MD, Christoph Maintz, MD, Norbert Gattermann, MD PhD, Uwe Platzbecker, MD, Eray Goekkurt, MD, Ina Boeters, MD, Richard Hansen, MD, Fabian Lang, MD, Joachim R. Goethert, Karla Bennemann, MD, Christoph Rollig, MD MSC, Hubert Serve, MD, Wolfgang E Berdel, MD, Gerhard Ehninger, MD, Tim H Bruemmendorf, MD, Steffen Koschmieder, MD

Blood (2014) 124 (21): 5561.

https://doi.org/10.1182/blood.V124.21.5561.5561

Published: 2014

Journal Articles

Dissecting Genomic Aberrations In CML and Bcr-Abl Negative Myeloproliferative Neoplasms By The Use Of Multiplex-PCR and Parallel Resequencing

Martin M. Kirschner, Mirle Schemionek, Claudia Schubert, Nicolas Chatain, Stephanie Sontag, Susanne Isfort, Nadina Ortiz-Brüchle, Karla Bennemann, Klaus Zerres, Martin Zenke, Tim H. Bruemmendorf, MD, Steffen Koschmieder

Blood (2013) 122 (21): 1612.

https://doi.org/10.1182/blood.V122.21.1612.1612

Published: 2013

Journal Articles

Validity of Inclusion/Exclusion Criteria in Clinical Trials for Myelofibrosis and the Need for Expanded Access Programs [More Expanded Access Programs Are Needed to Assess the Impact of Comorbidity and Comedication in Patients with Myelofibrosis]

Susanne Isfort, MD, Edgar Jost, MD, Karla Bennemann, MD, Martina Crysandt, MD, Sema Akin, Tim H Brümmendorf, Steffen Koschmieder, MD

Blood (2012) 120 (21): 5063.

https://doi.org/10.1182/blood.V120.21.5063.5063

Published: 2012

Journal Articles

Epigenetic Downregulation of Secreted Frizzled-Related Proteins In Philadelphia Positive and Philadelphia Negative Myeloproliferative Neoplasms

Karla Bennemann, MD, Claudia Schubert, Stefan Wilop, MD, Tim H. Brummendorf, MD, Oliver Galm, MD, Edgar Jost, MD

Blood (2010) 116 (21): 4647.

https://doi.org/10.1182/blood.V116.21.4647.4647

Published: 2010

NARROW

Comorbidity Scales in Patients with Myeloproliferative Neoplasms: Which One Fits Best?

Diagnosis and Treatment of Myeloproliferative Neoplasms in Germany: First Results from the SAL-MPN Registry

Dissecting Genomic Aberrations In CML and Bcr-Abl Negative Myeloproliferative Neoplasms By The Use Of Multiplex-PCR and Parallel Resequencing

Validity of Inclusion/Exclusion Criteria in Clinical Trials for Myelofibrosis and the Need for Expanded Access Programs [More Expanded Access Programs Are Needed to Assess the Impact of Comorbidity and Comedication in Patients with Myelofibrosis]

Epigenetic Downregulation of Secreted Frizzled-Related Proteins In Philadelphia Positive and Philadelphia Negative Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Comorbidity Scales in Patients with Myeloproliferative Neoplasms: Which One Fits Best?

Diagnosis and Treatment of Myeloproliferative Neoplasms in Germany: First Results from the SAL-MPN Registry

Dissecting Genomic Aberrations In CML and Bcr-Abl Negative Myeloproliferative Neoplasms By The Use Of Multiplex-PCR and Parallel Resequencing

Validity of Inclusion/Exclusion Criteria in Clinical Trials for Myelofibrosis and the Need for Expanded Access Programs [More Expanded Access Programs Are Needed to Assess the Impact of Comorbidity and Comedication in Patients with Myelofibrosis]

Epigenetic Downregulation of Secreted Frizzled-Related Proteins In Philadelphia Positive and Philadelphia Negative Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only